Opiant Pharmaceuticals, with its team of addiction experts, is headquartered in Santa Monica, California. The Company, formerly known as Lightlake Therapeutics, was founded in 2009 by the late Dr. David Sinclair based on his pioneering research demonstrating that opioid antagonists could be used as a symptom-driven treatment for alcoholism.
Building on the foundation of Dr. Sinclair’s pivotal work, Opiant uses opioid antagonist nasal sprays for symptom-driven treatments of substance use and eating disorders. With our innovative opioid antagonist nasal delivery technology, we are positioned to become a leader in developing pharmacotherapies for addictions and related disorders. The Company currently has one marketed and three pipeline products in its portfolio. In response to the opioid overdose epidemic, Opiant refocused its efforts to develop the first and only FDA-approved, user-friendly nasal naloxone spray. In 2015 this product, NARCAN® Nasal Spray 4mg, became available in the United States and Canada through our commercial partner, Adapt Pharma. The FDA further approved a 2mg dose of NARCAN® Nasal Spray in 2017. Our clinical pipeline includes nasally-delivered opioid antagonists for Bulimia Nervosa and Alcohol Use Disorder. We have also in-licensed a novel heroin vaccine, developed by the Walter Reed Army Institute of Research (WRAIR) in collaboration with the National Institute on Drug Abuse (NIDA), a division of the National Institute of Health (NIH).